Meeting endpoints means better than NOTHING (saline solution), it does not mean it is at all competitive with any other leading NASH candidate. LL isn't close and certainly not a "breakthrough."
They are deceptive -- they didn't even report the secondary endpoint of fibrosis reduction. cT1 is not a well accepted endpoint and not used in virtually any of the other NASH trials other than as backup data point.
Look at Madrigal, Inventiva data for comparison. LL is not close.
News 
Market Data 
Discover 
AI
